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Abstract
Background: Critics of systematic reviews have argued that these studies often fail to inform clinical decision
making because their results are far too general, that the data are sparse, such that findings cannot be applied to
individual patients or for other decision making. While there is some consensus on methods for investigating
statistical and methodological heterogeneity, little attention has been paid to clinical aspects of heterogeneity.
Clinical heterogeneity, true effect heterogeneity, can be defined as variability among studies in the participants, the
types or timing of outcome measurements, and the intervention characteristics. The objective of this project was to
develop recommendations for investigating clinical heterogeneity in systematic reviews.
Methods: We used a modified Delphi technique with three phases: (1) pre-meeting item generation; (2) face-to
-face consensus meeting in the form of a modified Delphi process; and (3) post-meeting feedback. We identified
and invited potential participants with expertise in systematic review methodology, systematic review reporting, or
statistical aspects of meta-analyses, or those who published papers on clinical heterogeneity.
Results: Between April and June of 2011, we conducted phone calls with participants. In June 2011 we held the
face-to-face focus group meeting in Ann Arbor, Michigan. First, we agreed upon a definition of clinical
heterogeneity: Variations in the treatment effect that are due to differences in clinically related characteristics. Next,
we discussed and generated recommendations in the following 12 categories related to investigating clinical
heterogeneity: the systematic review team, planning investigations, rationale for choice of variables, types of clinical
variables, the role of statistical heterogeneity, the use of plotting and visual aids, dealing with outlier studies, the
number of investigations or variables, the role of the best evidence synthesis, types of statistical methods, the
interpretation of findings, and reporting.
Conclusions: Clinical heterogeneity is common in systematic reviews. Our recommendations can help guide
systematic reviewers in conducting valid and reliable investigations of clinical heterogeneity. Findings of these
investigations may allow for increased applicability of findings of systematic reviews to the management of
individual patients.
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Background
There are several possible sources of variability or het-
erogeneity among studies that are included in systematic
reviews and meta-analyses. Variability in the partici-
pants, the types or timing of outcome measurements,
and intervention characteristics has been termed clinical
heterogeneity [1]; variability in the trial design or execu-
tion is commonly termed methodological heterogeneity
[2]; variability in summary treatment effect estimates
among trials is termed statistical heterogeneity [1].
These sources of heterogeneity are not necessarily mutu-
ally exclusive. For example, statistical heterogeneity may
arise from clinical or methodological heterogeneity, from
other unknown or unrecorded trial characteristics, or it
may be due to chance.
Another way of characterizing sources of heterogen-
eity of the estimated effect (association) among studies
in meta-analyses is outline in the following 3 items. 1.
True effect variation among studies (“clinical heterogen-
eity”) – due to; a. individual characteristics in the popu-
lation (e.g., age, disease severity, comorbidities) – i.e.,
individual modifiers of the treatment/exposure effect; b.
population context (e.g., type of setting or organization,
practice pattern) – i.e., contextual modifiers of the treat-
ment/exposure effect; c. type or nature of the treatment
or exposure (e.g., dose or frequency); d. choice of out-
come measure; e. choice of effect measure and follow-up
period (e.g., risk or rate ratio, risk or rate difference). 2.
Within-study estimation error variation among studies
(“methodological heterogeneity”) – due to; a. Random
error – low power for detecting effects due to small
sample sizes, rare outcome events, or weak associations;
and poor estimation precision (wide confidence inter-
vals); b. Bias due to confounding (e.g., confounding by
indication), selection or participation of subjects (which
depends on the outcome or outcome risk), or measure-
ment error; c. Bias due to model misspecification (e.g.,
due to ignored interactions or sparse data); d. Temporal
ambiguity between hypothesized predictors and out-
comes (e.g., due to design limitations, statistical limita-
tions, or reverse causation). 3. Between-study estimation
error in the meta-analysis (“methodological heterogen-
eity”)– due to: a. Aggregated data from studies used as
covariates in meta-regression or subgroup analysis (e.g.,
mean age or proportion of males) – a form of ecologic
bias; b. Misspecification of the meta-regression model; c.
Random error – low power and precision due to a
small number of studies; d. Publication bias – selective
reporting and publication of results.
In general, clinical heterogeneity may arise from differ-
ences in participant characteristics (i.e., Patient-level var-
iables; e.g., sex, age, baseline disease severity, ethnicity,
comorbidities), types or timing of outcome measure-
ments, and intervention characteristics (i.e., Study level
variables; e.g., dose and frequency of dose) [1]. Clinical
heterogeneity can cause substantively important statis-
tical heterogeneity, varying summary effect estimates
and associated conclusions, potentially misleading deci-
sion makers and other end-users of systematic reviews.
Systematic reviews and meta-analyses are frequently
recognized as the best available evidence for decisions
about health-care management and policy [3,4]. As such,
results of systematic reviews are incorporated into
clinical practice guidelines [5], sometimes required by
granting agencies in funding applications [6] and a grow-
ing body of experts devote considerable time to complet-
ing them [7]. In spite of the documented importance of
systematic reviews, it appears health-care professionals
and policy makers infrequently use systematic reviews to
guide decision-making [8]. This may be due to several
factors. For example, a limitation of many systematic re-
views is that their content and format are frequently not
useful to decision makers and reasons for heterogeneity
are not frequently explored leading to inconclusive and
non-specific results [8-10]. While guidance exists de-
scribing what to include in reports of systematic reviews
(e.g., the PRISMA statement) [11], characteristics of the
intervention that are necessary to apply their findings
are frequently not provided [12-14]. This has led to
some preliminary work on how to extract clinically rele-
vant information from systematic reviews [15]. Further-
more, systematic reviews commonly show substantial
heterogeneity in estimated effects, possibly due to meth-
odological, clinical or other unknown features (e.g.,
missing or unpublished data) in the included trials [16].
But, the reasons for or sources of heterogeneity are in-
frequently explored [9,10]. Thus, systematic reviewers
need to consider how best to handle sources of hetero-
geneity [1].
While guidance exists on the assessment and investi-
gation of methodological [1] and statistical heterogeneity
[1,17], little attention has been given to clinical hetero-
geneity [18]. The purpose of this project was to develop
consensus and empirically based recommendations for
investigating clinical heterogeneity in systematic reviews.
Methods
We used a modified Delphi method in which we contac-
ted participants by phone, convened a face-to-face focus
group, and finally asked for post-meeting feedback on
the completed manuscript.
First, we compiled a list of participants with expertise
or an interest in clinical heterogeneity who met one or
more of the following inclusion criteria: 1) publication of
guidance on how to investigate aspects of clinical het-
erogeneity in systematic reviews of clinical trials; 2)
publication of a manual or handbook for performing sys-
tematic reviews; 3) publication of a systematic review of
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guidelines for performing investigations of heterogeneity
in systematic reviews; 4) publication of reporting guide-
lines for systematic review of clinical trials; 5) member-
ship in the PRISMA Group or one of the Cochrane
Collaboration Handbook editors. These individuals were
identified by reviewing published papers, reports [18]
and conference abstracts. Next, we contacted individuals
by e-mail to determine their interest in participating.
Those individuals who agreed to participate scheduled
pre-meeting phone calls with one of the investigators
(JG). To generate discussion items for the face-to-face
meeting, each participant was asked, “What procedures
or covariates do you deem to be required for investigat-
ing clinical heterogeneity between or within clinical
trials in systematic reviews (qualitative or quantitative)?”
Individuals were asked for empirical or logical reasoning
for each suggestion as well as possible citations. After
contacting each individual, recommendations were
grouped by theme together with their rationale and
operational definitions. In May and June 2011, we
conducted phone calls with participants.
The face-to-face group meeting was led by one investi-
gator (JG) during a two-day meeting. On June 3rd and
4th, 2011, we held the face-to-face focus group meeting
in Ann Arbor, in which a total of 18 participants
attended and participated. They were an international
group (Canada, USA, United Kingdom, Germany, and
Austria) from several disciplines, including clinical re-
search, epidemiology, statistics, methodology, surgery,
clinical trials, and social science (see Additional file 1 for
a list of all participants). Participants were reminded
during all discussions that we were seeking recommen-
dations specifically associated with investigating clinical
heterogeneity in systematic reviews. During day one we
gave a background for the project and the results of a
recent methodological review in the area [18]; we also
presented the results of the pre-meeting item-recom-
mendation generation phase. We then asked for any
additional new items to be added to the discussion
items. Next, we proceeded to discuss each item in turn,
debating the need for each and presenting empirical evi-
dence where available. It was reiterated several times
that the goal of the meeting was to generate a list of rec-
ommendations. There was an open discussion of each
item during which clarifications, opinions, justifications,
operational definitions and new ideas were expressed.
Day two continued with this round table discussion and
debate. On each day, we also included small-group
break-out sessions. During day one, the purpose of the
break-out session was to discuss items or topics that
may not have been covered well in the discussions thus
far and to make recommendations to the larger group
on items that required attention. During day two, the
break-out session was focused around providing a
summary of the most relevant and significant recom-
mendations arising from this meeting. Once we had
discussed all items and a formal set of recommendations
were agreed upon, in a preliminary form, we adjourned
the meeting.
After the meeting, we drafted a manuscript describing
in brief the meeting results. The manuscript draft was cir-
culated to all meeting participants and several other indi-
viduals for their review and feedback. The manuscript was
then revised incorporating all participants feedback.
We received ethics approval from the University of
Michigan: HUM00043487. This study was funded by the
National Library of Medicine: NIH Grant 5R21LM010832-
02. The funding body had no role in the design, implemen-
tation or interpretations of the results of this project.
Results
Below we begin with a brief discussion of the agreed-upon
definition of clinical heterogeneity, elaborate on each spe-
cific recommendation and we present a table that includes
a summary of the group’s 12 recommendations.
Definition of clinical heterogeneity
Clinical heterogeneity, in the context of systematic re-
views, can be defined as differences in clinically related
characteristics that can give rise to variations in pooled
treatment effects estimates. Using the vocabulary of this
paper, clinical heterogeneity can be thought of as clinical
variability that results in true effect heterogeneity. The
group agreed that although the term “clinical heterogen-
eity” does not clearly represent the underlying concept,
the term is pervasive in the literature and therefore
should continue to be used. Though the term “clinical”
may appear to relate specifically to a patient, it is the
wider clinical context (e.g., patient, physician, treatment,
etc.) that is inferred in the above definition. Examples of
clinically related variables include:
 Patient/participant characteristics: age, sex, baseline
severity, genetic diversity, psychosocial aspects of the
population (e.g., equity, socioeconomic status, gender)
 Treatment/intervention characteristics: dose, timing,
route, personnel, level of training, comparator (e.g.,
other treatment or no treatment)
 Outcome/measurement characteristics: type of
event, outcomes measure, timing, effect estimate
 Study setting: time of year, geographic setting, where
data collected
Recommendations for investigating clinical heterogeneity in
systematic reviews
Table 1 provides an overview of the recommendations that
resulted from our meetings. We present the category or
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Table 1 Recommendations for investigating clinical heterogeneity in systematic reviews
Recommendation category Summary description
Review team It is recommended to have at least one or two individuals with clinical expertise, and at least one or
two individuals with methodological expertise in systematic reviews/meta-analyses and on the type of
study designs you are including [19,20]. The team should recognize their own biases and attempt to
compensate by including members with a wide range of (potentially conflicting) beliefs.
Planning All investigations of clinical heterogeneity should ideally be pre-planned a priori and not be driven by
observing the data [1,17,21-35]. But, methods for looking at data to identify unanticipated variables of
interest (i.e., post-hoc investigations) need to be pre-specified, as well (e.g., looking at summary tables,
graphical displays) [24,27,28,32,36]. Describe the following: which variables you will investigate, how this
will be done, when you will perform these investigations, and how results will be interpreted and
incorporated into your results and conclusions.
Rationale Variables should have a clear scientific rationale for their role as a treatment effect modifier (e.g.,
pathophysiological, pharmacologic, evidence from prior research, clinical experience)
[1,7,17,20,26,27,32-34,37,38]. Exercise parsimony in defining variable choices [1,20,28,33,39], and consider
that if variables are not reported, this may be due to an under reporting problem in primary studies.
That is, not finding an effect for clinically relevant variables does not imply a consistency of effect [20].
Types of clinical variables to consider Patient level: Age, baseline disease severity, sex, gender, ethnicity, comorbidities, genetic, other
psychosocial variables, and other important features of the disease [2,3,7,16].
Intervention level: Dose/strength/intensity of treatment, duration of treatment, brand/manufacturer, co-
interventions, timing, route of administration, compliance, clinician training, implementation, other
[1,2,4,5,8,12].
Outcome level: Event type, outcome measure type, outcome definition, length of follow-up, timing of
outcome measurement(s) [1,2,4-6].
Other: Research setting, geographical issues, length of follow-up [1,3,4].
Role of statistical heterogeneity Reviewers should think through all potentially relevant variables to explore and not rely on statistical
measures of heterogeneity to justify such investigations [1,20,40,41]. Clinical heterogeneity related to
specific individual factors could be present even in the absence of a significant statistical test for the
presence of heterogeneity (e.g., Cochran’s Q test) [24,27,31,36].
Plotting and visual aids Consider using graphical displays of data from trials to help identify potential clinical reasons for
heterogeneity. Examples of plotting and visual aids of the data include: summary data sheets [27], forest
plots [27,28,31,32,42], L’Abbé plots [24,32,43], funnel plots [24,44], Galbraith plots/radial plots [32],
influence plots [24,45,46], dose/response curves [4], multidimensional scaling [47], and heat maps [48,49].
Reviewers should be careful to avoid data dredging while using these methods of data display.
Dealing with outliers When there are individual trials that are clear outliers, attempt to determine why and consider a
sensitivity analysis where this/these trial(s) are eliminated and observe how the effect estimate changes.
One may also consider an influence analysis, in which the effect of deleting individual studies from the
analysis on the overall estimate is explored.
Number of investigations to perform and
variables to explore
Use parsimony as a guide to such investigations. A rule of thumb for the number of trials is that there
should be close to ten trials when working with summary or aggregate patient data (APD) or ten
individuals per variable, when working with pooled or individual patient data (IPD) [49-52]. Consider
making a hierarchy of clinically related variables and investigate only those variables for which your
rationale and power are sufficient.
The use of APD vs. IPD APD = summary or aggregate data from trials only. This is subject to ecological bias [30,51,53-55]—that
is, investigations of trial-level variables are valid (e.g., dose, duration), while investigations of patient-level
variables are not (e.g., age, baseline severity).
IPD = Original individual data on each patient. This type of data is valid for both trial-level and patient-
level variables [16,22,34-36,56-60]. But, one must control for baseline difference between the patients
across trials.
Consider contacting authors and reviewing protocols of primary studies where available. Obtaining IPD
for investigating clinically related patient-level variables is ideal.
The role of the best evidence syntheses Pre-plan to use a best evidence synthesis if the studies are not reasonably combinable. Be sure to pre-
plan criteria to determine combinability of included trials (e.g., sufficiently similar patient groups). This
approach can also be useful for exploring differences between/within the included studies. Several
recommendations for how to perform a narrative synthesis, for using levels of evidence or performing a
best evidence synthesis exist in the literature e.g., [61-63].
Statistical methods Many statistical methods are available for investigating the association of study findings with clinically
related variables, including frequentist, Bayesian and mixed methods. Stratification and various forms of
meta-regression can be useful. We recommend consulting respected texts and individuals with expertise
in the statistical methods of meta-analyses and explorations of heterogeneity, especially meta-regression
[23,27,28,32,35].
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topic of the recommendation and a description of what
the term(s) refer to as well as relevant references.
Assembling the review team
When preparing for writing a protocol, one must consider
the membership of the review team. This of course de-
pends on the research question and all of its components:
The population of interest, the intervention or exposure,
the control group if any, the outcome of interest and the
study design. In addition, when considering investigations
of heterogeneity, and specifically clinical heterogeneity,
the choice of review team members should be qualified by
the abilities to provide hypotheses. Generally, it is
recommended to have at least one or two individuals with
clinical expertise, and at least one or two individuals with
methodological expertise in systematic reviews/meta-ana-
lyses and on the type of study designs you are including
[19,20]. Furthermore, the team should recognize their
own biases and attempt to compensate by including mem-
bers with a wide range of (potentially conflicting) beliefs
concerning the hypotheses of interest.
Planning investigations of clinical heterogeneity
Following the formation of an investigative team, one
must plan, among other things, to investigate character-
istics considered to be clinical in nature. That is, all in-
vestigations of clinical heterogeneity should ideally be
pre-planned a priori and not be driven by observing the
data [1,17,21-35]. Pre-planned and a-priori are used as
synonymous terms here - they both mean before obser-
vation of the data.
One must acknowledge that systematic reviewers are
themselves subject to bias, similar to clinical trialists.
That is, it is generally not acceptable to observe the data
first to drive which variables to investigate since one is
potentially swayed by the data and not the hypotheses.
This potential bias exists whether we are talking about
primary studies (e.g., randomized controlled trials;
RCTs) or systematic reviews. Of course, the data, or
some of the data may be known by the scientists partici-
pating in the systematic review, as would be the case for
scientists performing an RCT. That is, when performing
an RCT it is expected that you know the prior research
and if you are choosing to stratify, you may do so for
variables and levels of those variables with good scien-
tific rationale from prior research. The same is the case
for prior knowledge and investigations of heterogeneity
in a systematic review. But in the case of systematic re-
views, it is expected that ALL of the data/studies are not
observed or scrutinzed so as to bias the choice of vari-
ables to investigate. While some of the studies will likely
be known, they are known for the same reasons studies
are known before performing RCTs. Of note, it is likely
that evidence from previous research may be referring to
a study that is itself included in the systematic review,
but this will not always be the case. For example, a large
observational study may suggest a variable of interest,
whereas a systematic review may have included only
subsequent RCTs. Overall, investigations of clinical het-
erogeneity should ideally be pre-planned a priori and
not be driven by observing the data.
As in RCTs, it is not uncommon for unanticipated var-
iables to be explored for their influence of treatment
effects in systematic reviews. That is, one may observe
completed summary extraction tables in a systematic re-
view and notice a trend in effect related to a clinical
variable. It is reasonable to pre-plan, a-priori, the
methods for looking at the included data to identify un-
anticipated variables of interest e.g., looking at summary
tables, graphical displays etc.; [24,27,28,32,36]. Of course,
such investigations are at a high risk of bias and should
be interpreted with caution and only used for hypothesis
generation. The results of any such investigations should
be confirmed in follow-up research.
Overall, it is recommended that the review authors
describe the following a priori: which variables will be
investigated, how this will be done, when the investiga-
tions will be performed, and how the results of such in-
vestigations will be interpreted and incorporated into
your results and conclusions.
Rationale
All variables planned for investigation must have a suffi-
cient scientific rationale for their role as a treatment
Table 1 Recommendations for investigating clinical heterogeneity in systematic reviews (Continued)
Interpretation of findings Results are generally observational and thus hypothesis generating only [1,23,24,28,33,53]. Authors
should express the validity of and confidence in their findings. When interpreting results of these
investigations it is suggested to consider: confounding, other sources of bias (e.g., publication,
misclassification, dilution, selection) [20,32], magnitude and direction of effect and CI [1,20], and thinking
through the plausibility of causal relationships [41]. It may not be appropriate to conclude that there is
consistency of effect if subgroup effects are not found [20]. Authors should use their findings to make
specific recommendations about how future research could proceed or build upon these results (not
just concluding that “more research is needed”).
Reporting Consider the potential for lack of reporting of data or information relating to clinical variables in the
primary studies. Consider contacting the authors for missing or additional data on important clinical
variables. Reviewers must be careful to report all of their proposed and actual investigations of clinical
heterogeneity. The PRISMA statement should be adhered to when reporting their reviews [11].
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effect modifier [1,7,17,20,26,27,32-34,37,38]. That is,
each variable chosen for investigation must have suffi-
cient, explicit, rationale for why and how it was chose.
Sources of such rationale may be pathophysiologic
mechanisms, evidence from prior clinical research, or
possibly from clinical experience. A brief description of
the rationale should be given with relevant citations and
empirical evidence where available. In such cases where
variables are chose after looking at the all combined data
from the included studies one should still attempt to
give a rational for that variable choice beyond it simply
being observed post-hoc. Of course, as mentioned above,
these post-hoc variable choices can be problematic and
should be treated with caution as bias is likely a factor.
Furthermore, it is recommended to exercise parsimony
in choosing variables [1,20,28,33,39]. That is, one should
choose only a small number of variables of highest im-
portance. The issue of power in these investigations is
discussed below under “Number of Investigations to
Perform and Variables to Explore”.
One must always be aware of the possible under-
reporting problem in primary studies included in sys-
tematic reviews e.g., [14]. The reporting of sufficient data
associated with clinically important variables is often
sub-par. That is, not finding an effect for clinically rele-
vant variables does not imply a consistency of effect
across variable that have a strong reason for being im-
portant [20]. We discuss reporting in more detail below.
Types of clinical variables to consider
The type of variables to choose, of course, depends in
the hypotheses that are being tested. But, we must be
careful to try to make explicit all existing rationale on
any variables, and attempt to find supporting data to
suggest which effect modifiers may be important. In
some cases no single clinical variable will be investigated
or be of interest in a systematic review. This is reason-
able since in some cases there is no reason to expect
true effect heterogeneity due to a specific clinical vari-
able. Of course, in many cases we expect that there are
several variables that can be considered to be effect
modifiers and that are clinical in nature. When defining
which variables may be considered “clinical” we recently
reviewed all relevant literature [18]. We referred closely
to these findings when giving the following examples of
variables one might consider.
For example, patient level clinical variables might in-
clude: Age, baseline disease severity, sex, gender, ethni-
city, comorbidities, genetic, other psychosocial variables,
and other important features of the disease [2,3,7,16].
Intervention level clinical variables include: Dose/
strength/intensity of treatment, duration of treatment,
brand/manufacturer, co-interventions, timing, route of
administration, compliance, clinician training, and
implementation [1,2,4,5,8,12]. Outcome level clinical
variables include: Event type, outcome measure type,
outcome definition, length of follow-up, and timing of
outcome measurement(s) [1,2,4-6]. And finally, other
clinical variables may include: Research setting, geo-
graphical issues, and length of follow-up [1,3,4].
Role of statistical heterogeneity
Statistical heterogeneity in systematic reviews is gener-
ally defined as variations in the estimated effect between
studies. Though a significant test for the presence of
statistical heterogeneity (e.g., Cochran’s Q test) and a
large degree of heterogeneity (e.g., I2 > 75%) might obli-
gate a reviewer to look for covariates to explain this vari-
ability, a nonsignificant test or a small I2 (e.g., <25%)
does not preclude the need to investigate covariate treat-
ment effect interactions [24,27,31,36]. Even with low
statistical heterogeneity, there may still be factors that
influence the size of the treatment effect, especially if
there is a strong argument (i.e., pathophysiologic or
otherwise) that some variable likely does have such an
influence. In particular, and related to the current paper,
clinical heterogeneity related to specific individual
factors could be present even in the absence of a signifi-
cant statistical test for the presence of heterogeneity
[24,27,31,36]. We suggest that reviewers should think
through all potentially relevant variables to explore and
not rely on statistical measures of heterogeneity to jus-
tify such investigations [1,20,40,41].
Plotting and visual aids
When one is examining data from the included studies in
a systematic review there are several plotting and visual
methods that appear to be promising. We recommend
that systematic reviewers consider using graphical displays
of data from trials to help identify potential clinical rea-
sons for heterogeneity. Examples of plotting and visual
aids of the data include: summary data sheets [27], forest
plots [27,28,31,32,42], L’Abbé plots [24,32,43], funnel plots
[24,44], Galbraith plots/radial plots [32], influence plots
[24,45,46], dose/response curves [4], multidimensional
scaling [47], and heat maps [48,49]. The citations associ-
ated with these methods give excellent guidance on how
to implement and interpret them.
There are potential drawbacks of using such methods
after inspecting the data. That is, one may use a plethora
of plotting and visual aids until an important effect for a
clinical variable is revealed. Thus reviewers using these
should be careful to avoid data dredging while using
these methods of data display.
Dealing with outliers
When there are individual trials that are clear outliers,
we recommend that systematic reviewers attempt to
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determine why and consider a sensitivity analysis where
this/these trial(s) are eliminated and observe how the
pooled effect estimate changes. One may also consider
an influence analysis, in which the effect of deleting indi-
vidual studies from the analysis on the overall estimate
is explored. Simply eliminating outliers is not a
recommended practice as this then biases the study in-
clusion and resulting data.
Number of investigations to perform and number of
variables to explore
An often cited rule of thumb for the number of trials is
that there should be close to ten trials when working
with summary or aggregate patient data (APD) or ten in-
dividuals per variable, when working with pooled or in-
dividual patient data (IPD). This rule of thumb derives
from work done in regression analyses in primary stud-
ies [50-52]. Additional studies have looked at this ques-
tion as well [64-67]. These studies describe a required
number of 4 to 20 events per variable depending on the
type of regression method and data structure being used.
But all of this evidence is related to primary studies and
regression analyses therein - not meta-regression. To
our knowledge, only 3 studies have looked at the type 1
error rate in meta-regression, but none of these tested
the required number of events per variable [26,68,69].
Thus, this is a rule of thumb, a heuristic, a general guid-
ing rule, and not supported by empirical evidence. What
appears to be clear is that the smaller number of in-
cluded studies, the more statistical heterogeneity, and
the more variables explored, the higher the type 1 error
rate [26,68,69]. Several methods are proposed to quell
this [26,68,69].
We also recommend that systematic reviewers con-
sider making a hierarchy of clinical variables of interest
and investigate only those variables for which your ra-
tionale and power are sufficient. Overall we suggest one
use the principle of parsimony or Ockam’s razor–
loosely translated as “do not multiply entities beyond the
extent necessary to explain a given phenomenon” - as a
guide to any such investigations.
The use of APD vs. IPD
It was our intent that the recommendations listed here
would be relevant to both APD and IPD meta-analyses.
But, we reasoned that some clarification of the power
and utility of each type of data should be described.
When data are collected from all participants included
in the trials that are themselves included in a systematic
review or meta-analysis, we term this individual patient
data (IPD). This data source has the obvious advantage
of allowing for valid investigations of clinical heterogen-
eity for both trial-level and patient-level variables
[16,22,34-36,56-60]. But, one must be careful to control
for baseline differences between the patients across trials
as this can bias the overall effect estimates in any hetero-
geneity investigations. Obtaining IPD for investigating
clinically related patient-level variables is ideal.
Aggregate patient data (APD), or summary patient
data from trials is by far the most common source of
data included in systematic reviews and meta-analyses.
One obvious problem with APD is that it is subject to
ecological bias [30,51,53-55]—that is, while results of in-
vestigations of trial-level variables that do not vary
across patients may be are valid (e.g., dose, duration of
treatment), results of investigations of patient-level vari-
ables (e.g., age, baseline severity) or trial level variables
that vary between patients (e.g., follow-up time) are sub-
ject to ecologic bias. Thus, systematic reviewers must be
cognizant of the potential drawback of both IPD and
APD meta-analyses.
We suggest that systematic reviewers consider
contacting authors and reviewing protocols of systematic
reviews, where available, to determine if plans for inves-
tigating particular clinical variables changed in any way
that be deemed biased.
The role of the best evidence syntheses
When performing a systematic review it may seem un-
reasonable to statistical combine the data from the in-
cluded studies for a variety of reasons including a lack of
or missing data and substantial heterogeneity between
the studies. When there is substantial heterogeneity it
can be ignored and a meta-analysis conducted with a
fixed-effects or random-effects model (incorporating
heterogeneity), one can attempt to explain the hetero-
geneity through subgroup analyses, meta-regression or
other techniques, or one can perform a best-evidence
synthesis. A best evidence synthesis entails looking at
the study quality, effects sizes and directions across in-
cluded studies to determine where possible effects are
present. Generally, a set of criteria are used to guide
such judgments and these qualities are discussed in the
systematic review itself and conclusions are made on the
overall evidence [1].
The Cochrane collaboration recently adopted the
Grades of Recommendation, Assessment, Development
and Evaluation (GRADE) criteria to aid in such assess-
ments. The GRADE criteria rate the body of evidence
for each outcome separately on: the types of study (ran-
domized vs nonrandomized), risk of bias (study quality),
publication bias (missing studies/small study effects), im-
precision (variability), inconsistency (similarity in point
estimates) and indirectness (heterogeneity) [1].
We suggest that systematic reviewers planning to per-
form a best evidence synthesis pre-plan their methods
for doing so. That is, we recommend they pre-plan how
to determine combinability of included trials (e.g.,
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sufficiently similar patient groups) and for exploring dif-
ferences between/within the included studies. Several
recommendations for how to use the GRADE approach,
performing a narrative synthesis, for using levels of evi-
dence, or performing a best evidence synthesis exist in
the literature e.g., [1,61-63].
Statistical methods
Many statistical methods are available for investigating
the association of study findings with clinically related
variables, including frequentist, Bayesian and mixed
methods. As noted in a recent publication, the number
and sophistication of techniques is constantly growing
[18]. Here we will briefly describe four available options
—subgroup analyses, meta-regression, the analogue to
the analysis of variance (ANOVA), and meta-analyses of
subgroups from primary studies.
Subgroup analyses involve separating trials into groups
relative to levels some characteristic (e.g., intervention
duration) and performing separate meta-analyses for
each group. This test provides an effect estimate within
subgroups and a significance test for that estimate. As
more subgroup analyses are done the likelihood of type
1 errors increase. There are some suggestions in the
literature for how to control for this e.g., [18]. To test
for differences between subgroups a moderator analysis
must be done. Moderator analyses include meta-
regression and the analogue to the ANOVA, among
other techniques e.g., Z test; [22]. Meta-regression is
similar to standard regression and is used to assess the
influence of independent variables (e.g., intervention
type) upon the dependent variable, the pooled treatment
effect estimate in a meta-analysis. Many separate types
of modeling strategies are available for meta-regression
e.g., [70]. Next, the analogue to the ANOVA examines
the difference in the effect between categorical levels of
some variable using statistical methods that are identical
to standard ANOVA e.g., [28].
Finally, it is acceptable combine subgroup effects from
within studies using separate meta-analyses e.g., [23]. Of
course, each separate meta-analysis done increases the
chance of type one errors, similar to performing multiple
subgroup analyses within a meta-analysis. Also, one
should be aware that subgroup analyses in a primary
study can still suffer from ecologic bias. Whereas sub-
groups that were preplanned and stratified in a primary
study, for example prior to randomization in an RCT,
can also be combined in meta-analyses, which have
much more validity than post-hoc, post randomization,
subgroup formation. Also, one must still be aware of the
role of additional variables beyond that which patients
were stratified on or divided into subgroups on the basis
of. That is, while subgroup effects may not be found, it
does not rule out effects for other variables.
We recommend that systematic reviewers attempting
to perform these analyses consult textbooks and individ-
uals with expertise in the statistical methods of
meta-analyses and explorations of heterogeneity e.g.,
[22,23,27,28,32,35].
Interpretation of findings
It was a consensus among the participants that the re-
sults of most investigations of clinical heterogeneity are
generally observational and thus hypothesis generating
only [1,23,24,28,33,53]. We recommend that the system-
atic reviewers should express the validity of and
confidence in their findings of investigations of clinical
heterogeneity. We also recommend that when interpre-
ting the results of such investigations to consider
confounding, other sources of bias e.g., publication, mis-
classification, dilution, selection; [20,32], magnitude and
direction of effect, variability in effect [1,20], and think-
ing through the plausibility of causal relationships for
potential influential clinical variables [41].
Furthermore, as briefly mentioned above, it may not
be appropriate to conclude that there is consistency of
effect when subgroup effects are not found [20]. Also,
authors should use their findings to make specific rec-
ommendations about how future research could proceed
or build upon these results and not simply and generally
conclude that “more research is needed”. That is, when
effects for clinical variable are found, or even trends in
effect on pooled estimates, when plausible, systematic
reviewers should recommend a confirmation of such
findings in follow-up research.
Reporting
It has been repeatedly recognized that there is poor
reporting in systematic reviews and in primary studies on
which they are based e.g., [11,14]. That is, in many cir-
cumstance the data or information required to perform an
investigation of some clinical variable may not be com-
pletely reported across any or all studies included in a sys-
tematic review. Thus, we recommend that systematic
reviewers consider the potential for lack of reporting of
data or information relating to clinical variables in the pri-
mary studies included in their reviews. Because of this,
one should consider contacting the authors for missing or
additional data on important clinical variables.
Furthermore, systematic reviewers must be careful to
report all of their proposed and actual investigations of
clinical heterogeneity. Some evidence suggests that sys-
tematic reviewers are currently not doing this and that
this could lead to confusion from those reading and
interpreting these investigations e.g., [71]. Reporting
guidelines exist for generic meta-analyses and for meta-
analyses of observations studies [11,72]. The PRISMA or
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MOOSE statement should be adhered to when reporting
systematic reviews and meta-analyses [11,72].
Discussion
We conducted a consensus development study, in the
form of a modified Delphi process, to develop recom-
mendations for investigating clinical heterogeneity in
systematic reviews of controlled studies. We expanded
upon findings from the empirical literature and added
several additional recommendations from a diverse
group of experts (Table 1). In particular we provide a
definition of clinical heterogeneity that can be used by
systematic reviewers and methodologists. This definition
focuses on characteristics that are clinically related and
that influence treatment effect estimates. It also focuses
squarely on variables as reflected in the magnitude of
statistical relation between it and an outcome variable.
Overall, we expect that these recommendations will aid
systematic reviewers in investigating differences among
and within studies and further improve the applicability
of systematic review findings.
To create our recommendations, we used a consensus
method, informed by empirical literature and expertise.
That is, some recommendations are not supported by
empirical evidence and therefore have unknown validity
for investigating clinical heterogeneity in systematic re-
views. We recommend that where possible these recom-
mendations be tested and revised as new knowledge
becomes available. However, we made every effort to
identify evidence for these recommendations and circu-
lated the findings to a wide audience of experts, beyond
those involved in the consensus process, to comment on
and revise our findings. In particular, we referred to a
comprehensive methodological review of published rec-
ommendations for investigating clinical heterogeneity
that was completed prior to the current project [18].
Therefore, we expect that these recommendations repre-
sent a well-grounded set of ideas to aid systematic re-
viewers in investigating clinical heterogeneity. Also,
while we focus in the paper on the concept of clinical
heterogeneity, many of these recommendations apply to
investigating other sources of heterogeneity (e.g., meth-
odological heterogeneity).
While there are many articles and resources in the lit-
erature providing recommendations for investigating
clinical heterogeneity in systematic reviews, few existing
resources include a relatively comprehensive set of rec-
ommendations on the topic [1,24,28]. In particular, the
Cochrane Handbook, which is regularly updated, does
provide some of the details we describe in Table 1 [1].
Other resources have also described methods for
performing statistical investigations of clinical hetero-
geneity e.g., [32].
Conclusions
Our recommendations are intended to assist investiga-
tors during several stages of completing a systematic re-
view. In particular, these recommendations will help
guide the planning of investigations of clinical hetero-
geneity, implementing such plans, and reporting the
findings. We suggest that such investigations, while
often observational, may improve the applicability of the
findings and their utility for decision-making.
We recommend that empirical work be carried out to
test each of these recommendations. We also welcome
critical feedback so that we may improve and further de-
velop these ideas to aid systematic reviewers and end
users of these studies. Finally, we hope that scientific
groups, editorial boards, and funding agencies consider
these recommendations when implementing, reviewing,
and funding systematic reviews. These efforts will im-
prove the validity and reliability of investigations of clin-
ical heterogeneity.
Additional file
Additional file 1: Participants in the Ann Arbor Clinical
Heterogeneity Consensus Group.
Competing interests
The authors declare receiving no support for this study from any
organization, have no financial relationships with any organizations that
might have an interest in the study, and have no other relationships or
activities that could appear to be conflicts of interests.
Authors’ contributions
JG, HM and DM conceived of the design, applied for funding, obtained ethics
approval, organized the meeting, interpreted the findings and wrote and edited
the manuscript. DA, JB, SC, PMcC, and XS contributed to and edited the
manuscript. All members listed in Additional file 1 contributed to the content of
this paper. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by a grant from the National Library of
Medicine: Grant # R21LM010832-02. We would also like to acknowledge two
research assistants on this project: Laura Chess and Patrick Kellam.
See Additional file 1 for a complete list of the Ann Arbor Clinical
Heterogeneity Consensus Group.
Author details
1Department of Orthopaedic Surgery, University of Michigan, MedSport, 24
Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA. 2Department of
Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI,
USA. 3Center for Statistics in Medicine, University of Oxford, Oxford, UK.
4Research and Development, Johnson and Johnson Pharmaceutical,
Philidelphia, PA, USA. 5Agency for Healthcare Research and Quality,
RockvilleMD, USA. 6Centre for Evidence Based Medicine, University of Oxford,
Oxford, UK. 7Kaiser Permanente Center for Health Research and Oregon
Evidence-based Practice Center, Oregon Health Sciences University, Portland,
OR, USA. 8Clinical Epidemiology Program, Ottawa Hospital Research Institute,
Ottawa, ON, Canada. 9Department of Epidemiology, University of Ottawa,
Ottawa, ON, Canada.
Received: 27 November 2012 Accepted: 22 August 2013
Published: 30 August 2013
Gagnier et al. BMC Medical Research Methodology 2013, 13:106 Page 9 of 11
http://www.biomedcentral.com/1471-2288/13/106
References
1. Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0 (updated March 2011); 2011. Available at:
www.cochrane-handbook.org. The Cochrane Collaboration.
2. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC:
Impact of allocation concealment on conclusions drawn from meta-
analyses of randomized trials. Int J Epidemiol 2007, 36(4):847–857.
3. Grimshaw JM, Santesso N, Cumpston M, Mayhew A, McGowan J:
Knowledge for knowledge translation: The role of the Cochrane
Collaboration. J Contin Educ Health Prof 2006, 26:55–62.
4. Tugwell P, Robinson V, Grimshaw J, Santesso N: Systematic reviews and
knowledge translation. Bull World Health Organ 2006, 84:643–651.
5. British Medical Journal. Clinical Evidence; 2009. Available at: http://
clinicalevidence.bmj.com/ceweb/about/index.jsp. Accessed 16 Feb 2009.
6. Canadian Institutes of Health Research; 2009. Available at: http://www.cihr-
irsc.gc.ca/e/documentsrct_reg_e.pdf. Accessed 16 Feb 2009.
7. Cochrane Collaboration. Available at: http://cochrane.org. Accessed 20 Nov
2012.
8. Laupacis A, Strauss S: Systematic reviews: Time to address clinical and
policy relevance as well as methodological rigor. Ann Int Med 2007,
147(4):273–275.
9. Barry MJ: Helping patients make better personal health decisions: The promise
of patient-centered outcomes research. JAMA 2011, 306(11):1258–1259.
10. Patient-Centered Outcomes Research Institute. Available at: http://www.pcori.
org/patient-centered-outcomes-research/. Accessed 1 May 2012.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred
reporting items for systematic review and meta-analyses: the PRISMA
statement. PLoS Med 2009, 6:e1000097.
12. Chalmers I, Glasziou P: Avoidable waste in the production and reporting
of research evidence. Lancet 2009, 374:86–89.
13. Glasziou P, Chalmers I, Altman DG, Bastian H, Boutron I, Brice A, Jamtvedt G,
Farmer A, Ghersi D, Groves T, Heneghan C, Hill S, Lewin S, Michie S, Parera
R, Pomeroy V, Tilson J, Sheppaard S, Williams JW: Taking healthcare
interventions from trial to practice. BMJ 2010, 341:c3852.
14. Glasziou P, Meats E, Heneghan C, Shepperd S: What is missing from
descriptions of treatment in trials and reviews? BMJ 2008, 336:1472–1474.
15. Scott NA, Moga C, Barton P, Rashiq S, Schopflocher D, Taenzer P, Harstall C,
on behalf of the Alberta Ambassador Program Team: Creating clinically
relevant knowledge from systematic reviews: The challenges of
knowledge translation. J Eval Clin Pract 2007, 13(4):681–688.
16. Thompson SG: Why sources of heterogeneity in meta-analysis should be
investigated. BMJ 1994, 309:1351–1355.
17. Higgins J, Thompson S, Deeks J, Altman A: Statistical heterogeneity in
systematic reviews of clinical trials: a critical appraisal of guidelines and
practice. J Health Serv Res Policy 2002, 7(1):51–61.
18. Gagnier JJ, Beyene J, Moher D, Boon H, Bombardier C: Methods of
assessing clinical heterogeneity in systematic reviews: A methodologic
review. BMC Med Res Methodol 2012, 12(1):111.
19. van den Ende CHM, Steultjens EMJ, Bouter LM, Dekker J: Clinical
heterogeneity was a common problem in Cochrane reviews of
physiotherapy and occupational therapy. J Clin Epidemiol 2006, 59:914–919.
20. West SL, Gartlehner G, Mansfield AJ, Poole C, Tant E, Lenfestey N, Lux LJ,
Amoozegar J, Morton SC, Carey TC, Viswanathan M, Lohr KN: Comparative
effectiveness review methods: clinical heterogeneity. In Comparative
Effectiveness Review Methods: Clinical Heterogeneity. Rockville, MD: Agency for
Healthcare Research and Quality; 2010. Available at http://effectivehealth
care.ahrq.gov/; posted 28 Sept 2010.
21. Bender R, Bunce C, Clarke M, Gates S, Lange S, Pace NL, Thorlund K:
Attention should be given to multiplicity issues in systematic reviews.
J Clin Epidemiol 2008, 61(9):857–865.
22. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI: Individual
patient- versus group-level data meta-regressions for the investigation
of treatment effect modifiers: ecological bias rears its ugly head.
Stat Med 2002, 21(3):371–387.
23. Borenstein MA, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-
Analysis. New Jersey: John Wiley and Sons; 2009.
24. Centre for Reviews and Dissemination: CRD’s Guidance for Undertaking
Reviews in Health Care. York: Centre for Reviews and Dissemination; 2009.
25. Cook DJ, Sackett DL, Spitzer WO: Methodologic guidelines for systematic
reviews of randomized control trials in health care from the Potsdam
Consultation on Meta-Analysis. J Clin Epidemiol 1995, 48(1):167–171.
26. Higgins JP, Thompson SG: Controlling the risk of spurious findings from
meta-regression. Stat Med 2004, 23(11):1663–1682.
27. Khalid S, Khan RK, Kleijnen J, Antes G: Systematic Reviews to Support
Evidence-based Medicine: How to Apply Findings of Health-Care Research.
London: Royal Society of Medicine Press Ltd.; 2003.
28. Littell JC, Corcoran J, Pillai VK: Systematic Reviews and Meta-Analysis. Oxford:
Oxford University Press; 2008.
29. Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R:
Method guidelines for Cochrane Musculoskeletal Group systematic
reviews. J Rheumatol 2006, 33(11):2304–2311.
30. Reade MC, Delaney A, Bailey MJ, Angus DC: Bench-to-bedside review:
Avoiding pitfalls in critical care meta-analysis–funnel plots, risk
estimates, types of heterogeneity, baseline risk and the ecologic fallacy.
Crit Care 2008, 12(4):220.
31. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG:
Meta-analysis of individual patient data from randomized trials: a review
of methods used in practice. Clin Trials 2005, 2(3):209–217.
32. Sutton AJ, Jones DR, Sheldon TA, Song F: Methods for Meta-analysis in
Medical Research. Chichester: John Wiley & Sons, Ltd.; 2000.
33. Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: a
comparison of methods. Stat Med 1999, 18(20):2693–2708.
34. Trikalinos TA, Ioannidis JP: Predictive modeling and heterogeneity of
baseline risk in meta-analysis of individual patient data. J Clin Epidemiol
2001, 54(3):245–252.
35. Whitehead A: Meta-Analysis of Controlled Clinical Trials. Chichester: John
Wiley & Sons, Ltd.; 2002.
36. National Health and Medical Research Council: How to Review the Evidence:
Systematic Identification and Review of the Scientific Literature. Australia:
Commonwealth of Australia; 2000.
37. Berkey CS, Anderson JJ, Hoaglin DC: Multiple-outcome meta-analysis of
clinical trials. Stat Med 1996, 15(5):537–557.
38. Furlan AD, Pennick V, Bombarider C, van Tulder M, from the Editorial Board
of the Cochrane Back Review Group: 2009 Updated method guidelines for
systematic reviews in the Cochrane Back Review Group. Spine 2009,
34(18):1929–1941.
39. Lipsey MW, Wilson DB: The way in which intervention studies have
"personality" and why it is important to meta-analysis. Eval Health Prof
2001, 24(3):236–254.
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2007, 327:557–560.
41. Shadish WR: Meta-analysis and the exploration of causal mediating
processes: A primer of examples, methods, and issues. Psychol Methods
1996, 1:47–65.
42. Hall JA, Rosenthal R: Interpreting and evaluating meta-analysis. Eval Health
Prof 1995, 18(4):393–407.
43. Song F: Exploring heterogeneity in meta-analysis: is the L'Abbe plot
useful? J Clin Epidemiol 1999, 52(8):725–730.
44. Sterne JA, Egger M, Smith GD: Systematic reviews in health care:
Investigating and dealing with publication and other biases in meta-
analysis. BMJ 2001, 323(7304):101–105.
45. Malling HJ, Thomsen AB, Andersen JS: Heterogeneity can impair the
results of Cochrane meta-analyses despite accordance with statistical
guidelines. Allergy 2008, 63(12):1643–1645.
46. Sutton A: Recent development in meta-analysis. Stat Med 2008, 27:625–650.
47. Bravata DM, Shojania KG, Olkin I, Raveh A: CoPlot: a tool for visualizing
multivariate data in medicine. Stat Med 2008, 27(12):2234–2247.
48. Horvath S, Dong J: Geometric interpretation of gene coexpression
network analysis. PLoS Comput Biol 2008, 4(8):e1000117.
49. Lanktree MB, Hassell RG, Lahiry P, Hegele RA: Phenomics: expanding the
role of clinical evaluation in genomic studies. J Investig Med 2010,
58(5):700–706.
50. Concato J, Peduzzi P, Holfold TR, Feinstein AR: Importance of events per
independent variable in proportional hazards analysis. I. Background,
goals, and general strategy. J Clin Epidemiol 1995, 48:1495–1501.
51. Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per
independent variable in proportional hazards regression analysis. II.
Accuracy and precision of regression estimates. J Clin Epidemiol 1995,
48:1503–1510.
52. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation
study of the number of events per variable in logistic regression
analysis. J Clin Epidemiol 1996, 49:1373–1379.
Gagnier et al. BMC Medical Research Methodology 2013, 13:106 Page 10 of 11
http://www.biomedcentral.com/1471-2288/13/106
53. Freemantle N, Mason J, Eccles M: Deriving treatment recommendations
from evidence within randomized trials. The role and limitation of
meta-analysis. Int J Technol Assess Health Care 1999, 15(2):304–315.
54. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic
reviews. Ann Intern Med 1997, 127(9):820–826.
55. Schmid CH, Lau J, McIntosh MW, Cappelleri JC: An empirical study of the
effect of the control rate as a predictor of treatment efficacy in meta-
analysis of clinical trials. Stat Med 1998, 17(17):1923–1942.
56. Lambert PC, Sutton AJ, Jones ADR: A comparison of patient-level
covariates in meta-regression with individual patient data meta-analysis.
J Clin Epidemiol 2002, 55:86–94.
57. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, Boutitie F:
Meta-analysis of continuous outcomes combining individual patient
data and aggregate data. Stat Med 2008, 27(11):1870–1893.
58. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected
associations between heterogeneous treatment effects and study-level,
but not patient-level, factors. J Clin Epidemiol 2004, 57(7):683–697.
59. Smith CT, Williamson PR, Marson AG: An overview of methods and
empirical comparison of aggregate data and individual patient data
results for investigating heterogeneity in meta-analysis to time-to-event
data. J Eval Clin Pract 2002, 55:86–94.
60. Thompson SG, Higgins JP: Treating individuals 4: can meta-analysis help
target interventions at individuals most likely to benefit? Lancet 2005,
365(9456):341–346.
61. Popay J, Roberts H, Sowden A, Petticrew M, Britten N, Arai L, Roen K,
Rodgers M: Developing methods for the narrative synthesis of quantitative and
qualitative data in systematic reviews of effects. Centre for Reviews and
Dissemination; 2006. Available at: http://www.york.ac.uk/inst/crd/projects/
narrative_synthesis.htm. Accessed 15 May 2012.
62. Rodgers M, Sowden A, Petticrew M, Arai L, Robers H, Britten N, Popay J:
Testing methodological guidance on the conduct of narrative synthesis
in systematic reviews, effectiveness of interventions to promote smoke
alarm ownership and function. Evaluation 2009, 15(1):49–74. http://dx.doi.
rg/10.1177/1356389008097871.
63. van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method
guidelines for systematic reviews in the Cochrane Collaboration Back
Review Group. Spine (Phila Pa 1976) 2003, 28(12):1290–1299.
64. Flack V, Change PC: Frequency of selecting noise variables in subset
regression analysis: a simulation study. Am Stat 1989, 41:84–86.
65. Freedman LS, Pee D: Return to a note on screening regression equations.
Am Stat 1989, 43:279–282.
66. Freedman LS, Pee D, Midthune DN: The problem of understanding the
residual error variance in forward stepwise regression. Statistician 1992,
41:405–412.
67. Couvoisier DS, Combescure C, Agoristsas T, Gayet-Ageron A, Pergneger TV:
Performance of logistic regression modeling: beyond the number of
events per variable, the role of data structure. J Clin Epidemiol 2011,
64(9):993–1000.
68. Huizenga HM, Visser I, Dolan CV: Testing overall and moderator effects in
random effects meta-regression. Br J Math Stat Psychol 2011, 64(1):1–19.
69. Gagnier JJ, Bombardier C, Boon H, Moher D, Beyene J: An empirical study
using permutation-based resampling in meta-regression. Syst Rev 2012, 1:18.
70. Baker W, White M, Cappelleri JC, Kluger J, Colman CI: Understanding
heterogeneity in meta-analysis: the role of meta-regression. Int J Clin
Pract 2009, 63(10):1426–1434.
71. Gagnier JJ, Chess L: Quality of reporting of investigations of clinical
heterogeneity in systematic reviews. Auckland New Zealand: Poster
Presentation: Cochrane Colloquium, 2012; 2013.
72. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D,
Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008–2012.
doi:10.1186/1471-2288-13-106
Cite this article as: Gagnier et al.: Consensus-based recommendations
for investigating clinical heterogeneity in systematic reviews. BMC
Medical Research Methodology 2013 13:106.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gagnier et al. BMC Medical Research Methodology 2013, 13:106 Page 11 of 11
http://www.biomedcentral.com/1471-2288/13/106
